


IN THE CLAIMS:

Under 37 C.F.R. § 1.121(c), please amend the claims as indicated below.

- (Currently amended) A compound according to the formula (I):



or a pharmaceutically acceptable salt, solvate, or polymorph thereof, wherein R¹ is H or a C₁-C₄ alkyl group;

R² is a $\text{—}\overset{\text{O}}{\parallel}\text{C—R}^3$ group, a $\text{—}\overset{\text{O}}{\parallel}\text{P—R}^4$ group or an OR group; wherein R³ is H, a C₁-C₂₀ alkyl group, an OR group, an alkylene ester group

$\text{—}(\text{CH}_2)_n\text{—}\overset{\text{O}}{\parallel}\text{C—OR}^{10}$, an amine group $\text{—NR}^{11}\text{R}^{12}$ or; or R³ and R⁶ are taken together to form a $\text{—}(\text{CH}_2)_m\text{—}$ group where m is 1-3 and forms a ring with R⁶, R is a C₁-C₂₀ alkyl group, an aryl group or an alkylene aryl group, R¹⁰ is a C₁-C₁₀ alkyl group, n is 1 to 20, R¹¹ is selected from the group consisting of H, C₁-C₄ alkyl, aryl, alkylene aryl or and an alkylene ester group as described above, and R¹² is selected from the group consisting of H, C₁-C₄ alkyl, aryl, alkylene aryl or and an alkylene ester group as described above or is; or R¹² and R⁶ are taken together to form a $\text{—}(\text{CH}_2)_z\text{—}$ group where z is 0 to 2, such that R¹² forms a ring with R⁶, and wherein when at least one of R¹¹ and R¹² is other than H, the other of R¹¹ or R¹² is H; R⁶ is H, C₁-C₄ alkyl, F, Cl, Br, I, NO₂ or a NR¹³R¹⁴ group where R¹³ is and R¹⁴ are H or a C₁-C₃ alkyl group; or and R¹⁴ is taken together with R³ to form a $\text{—}(\text{CH}_2)_p\text{—}$ group where p is 0 to 3 a—

$\text{—}\overset{\text{O}}{\parallel}\text{C—R}^3$ group when R³ is absent; R⁴ and R⁵ are aryl or aryloxy; and each of R⁷, R⁸ and R⁹ is independently selected from H, C₁-C₄ alkyl, F, Cl, Br, I or and NO₂.

- (Previously presented) The compound of claim 1 selected from the group consisting of:

N-(4-Pyridyl) *t*-Butyl Carbamate;
N-(4-Pyridyl) Ethyl Carbamate;
N-(4-Pyridyl) Methyl Carbamate;

N-(4-Pyridyl) Isopropyl Carbamate;
N-(4-Pyridyl) Dodecyl Carbamate;
N-(4-Pyridyl) Benzyl Carbamate;
N-(4-Pyridyl) Benzamide;
N-(4-Pyridyl) Acetamide;
N-(4-Pyridyl) Propionamide;
N-(4-Pyridyl) Trimethylacetamide;
N-(4-Pyridyl) Ethyl Succinamate;
N, N'-(4-Pyridyl) Urea;
N, N'-(3,4-Pyridyl) Urea;
P, P-Diphenyl *N*-(4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramidic acid, Diphenyl Ester; and
a pharmaceutically acceptable salt, solvate, or polymorph thereof.

3. (Previously presented) A pharmaceutical composition for the treatment of injured mammalian nerve tissue, comprising a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof.

4. (Previously presented) The pharmaceutical composition of claim 3, wherein the compound is selected from the group consisting of:

N-(4-Pyridyl) *t*-Butyl Carbamate;
N-(4-Pyridyl) Ethyl Carbamate;
N-(4-Pyridyl) Methyl Carbamate;
N-(4-Pyridyl) Isopropyl Carbamate;
N-(4-Pyridyl) Dodecyl Carbamate;
N-(4-Pyridyl) Benzyl Carbamate;
N-(4-Pyridyl) Benzamide;
N-(4-Pyridyl) Acetamide;
N-(4-Pyridyl) Propionamide;
N-(4-Pyridyl) Trimethylacetamide;
N-(4-Pyridyl) Ethyl Succinamate;
N, N'-(4-Pyridyl) Urea;
N, N'-(3,4-Pyridyl) Urea;
P, P-Diphenyl *N*-(4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramidic acid, Diphenyl Ester;

and pharmaceutically acceptable salts, solvates, and polymorphs thereof.

5. - 14. (Canceled)

15. (Previously presented) The compound of claim 1, wherein R^1 , R^6 , R^7 , R^8 and R^9 are each H; and R^2 is a $-C(O)R^3$ group, wherein R^3 is $-OCH_2CH_3$.

16. (New) The compound of claim 1 wherein at least two of R^7 , R^8 , and R^9 are H.

17. (New) The compound of claim 1 wherein R^7 , R^8 , and R^9 are each H.